Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

MODUS THERAPEUTICS Aktie

>Performance

1 Woche: 0%

1 Monat: +1,3%

3 Monate: +1,7%

6 Monate: -19,5%

1 Jahr: +29,6%

laufendes Jahr: -19,5%

>MODUS THERAPEUTICS Aktie

Name:

MODUS THERAPEUTICS HLDG

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0015987904 / A3CVSY

Symbol/ Ticker:

99Z (Frankfurt)

Kürzel:

FRA:99Z, ETR:99Z, 99Z:GR

Index:

Webseite:

https://www.modustx.com/

Marktkapitalisierung:

4.75 Mio. EUR

Umsatz:

EBITDA:

Gewinn je Aktie:

-0.04 EUR

Schulden:

5 Mio. EUR

Liquide Mittel:

5.32 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 21.9 / -

Gewinnm./ Eigenkapitalr.:

- / -219.51%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

MODUS THERAPEUTICS, MODUS THERAPEUTIC

Letzte Datenerhebung:

04.07.25

>Eigentümer

Aktien: 35.94 Mio. St.

f.h. Aktien: 2.15 Mio. St.

Insider Eigner: 88.55%

Instit. Eigner: 0.9%

Leerverk. Aktien: -

>Peer Group

ASCELIA

BIO-WORKS TECHNOLOGIES

BIOTAGE

BONESUPPORT

CELLAVISION

GUARD THERAPEUTICS

MENTICE

ONCOPEPTIDES

PILA PHARMA

QUIA PHARMA

>Chart & Kurs - Frankfurt
- Boerse Frankfurt
- >Profi Charts

>Alle News

27.06.25 - 16:51	Karolinska Development′s portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million (GlobeNewswire EN)
	STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia....

09.12.24 - 14:06	Karolinska Development′s portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia (GlobeNewswire EN)
	STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2 clinical study of the drug candidate sevuparin, evaluated as a treatment for chronic kidney disease with anemia. The study is being conducted at Centro Ricerche Cliniche di Verona in Italy....

19.11.24 - 17:24	Karolinska Development′s portfolio company Modus Therapeutics secures bridge financing (GlobeNewswire EN)
	STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company's largest shareholder. The funding enables Modus to initiate the recently approved phase 2a study in chronic kidney disease....

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Im Winter beim Ofen, im Sommer im Feld. - Bauernregel - Bauernweisheit

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram